Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
<Composition xmlns="http://hl7.org/fhir">
<id value="372776"/>
<meta>
<versionId value="30"/>
<lastUpdated value="2025-08-14T13:00:00.289Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence-report-expanded"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Composition 372776</b></p><a name="372776"> </a><a name="hc372776"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 30; Last updated: 2025-08-14 13:00:00+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-comparative-evidence-report-expanded.html">ComparativeEvidenceReportExpanded</a></p></div><p><b>Artifact Description</b>: </p><div><p>This is an example of a Comparative Evidence Report describing the QUARTET USA Randomized Controlled Trial for the EBM on FHIR Implementation Guide.</p>
</div><p><b>ArtifactPublicationStatus</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}">Active</span></p><p><b>url</b>: <a href="https://fevir.net/resources/Composition/372776">https://fevir.net/resources/Composition/372776</a></p><p><b>identifier</b>: FEvIR Object Identifier/372776</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ComparativeEvidenceReport}">Comparative Evidence Report</span></p><p><b>date</b>: 2025-08-14 13:00:00+0000</p><p><b>author</b>: Joanne Dehnbostel</p><p><b>title</b>: Comparative Evidence Report for QUARTET USA Trial</p><p><b>custodian</b>: <a href="Organization-118079.html">Computable Publishing LLC</a></p><h3>RelatesTos</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style="display: none">*</td><td>Cite As</td><td><div><p>Comparative Evidence Report for QUARTET USA Trial [Database Entry: FHIR Composition Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 372776. Revised 2025-08-14. Available at: https://fevir.net/resources/Composition/372776. Computable resource at: https://fevir.net/FLI/DocumentForComposition372776.</p>
</div></td></tr></table></div>
</text>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-description">
<valueMarkdown
value="This is an example of a Comparative Evidence Report describing the QUARTET USA Randomized Controlled Trial for the EBM on FHIR Implementation Guide."/>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status">
<valueCodeableConcept>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"/>
<code value="active"/>
<display value="Active"/>
</coding>
</valueCodeableConcept>
</extension>
<url value="https://fevir.net/resources/Composition/372776"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net/FOI"/>
<value value="372776"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="ComparativeEvidenceReport"/>
<display value="ComparativeEvidenceReport"/>
</coding>
<text value="Comparative Evidence Report"/>
</type>
<date value="2025-08-14T13:00:00.289Z"/>
<author>
<display value="Joanne Dehnbostel"/>
</author>
<title value="Comparative Evidence Report for QUARTET USA Trial"/>
<custodian>🔗
<reference value="Organization/118079"/>
<type value="Organization"/>
<display value="Computable Publishing LLC"/>
</custodian>
<relatesTo>
<type value="cite-as"/>
<targetMarkdown
value="Comparative Evidence Report for QUARTET USA Trial [Database Entry: FHIR Composition Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 372776. Revised 2025-08-14. Available at: https://fevir.net/resources/Composition/372776. Computable resource at: https://fevir.net/FLI/DocumentForComposition372776."/>
</relatesTo>
<section>
<title value="Introduction Section"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="introduction"/>
<display value="Introduction"/>
</coding>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><span style="color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">New approaches are needed to lower blood pressure (BP) given persistently low control rates. QUARTET USA sought to evaluate the effect of four-drug, quarter-dose BP lowering combination in patients with hypertension. </span></p></div>
</text>
</section>
<section>
<title value="Study Sample"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="study-sample"/>
<display value="Study Sample"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<entry>🔗
<reference value="Group/372797"/>
<type value="Group"/>
<display value="Enrolled Group for QUARTET USA Trial"/>
</entry>
<section>
<title value="Eligibility Criteria"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="eligibility-criteria"/>
<display value="Eligibility Criteria"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<entry>🔗
<reference value="Group/372778"/>
<type value="Group"/>
<display value="Eligibility Criteria for QUARTET USA Trial"/>
</entry>
</section>
</section>
<section>
<title value="Intervention Group"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="intervention-group"/>
<display value="Intervention Group"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<entry>🔗
<reference value="Group/375175"/>
<type value="Group"/>
<display value="QUARTET USA Trial Quadpill group"/>
</entry>
<section>
<title value="Intervention Description"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="intervention-description"/>
<display value="Intervention Description"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<entry>🔗
<reference value="ActivityDefinition/375159"/>
<type value="ActivityDefinition"/>
<display value="Quadpill once daily"/>
</entry>
</section>
</section>
<section>
<title value="Comparator Group"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="comparator-group"/>
<display value="Comparator Group"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<entry>🔗
<reference value="Group/375182"/>
<type value="Group"/>
<display value="QUARTET USA Trial Control Group"/>
</entry>
<section>
<title value="Comparator Description"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="comparator-description"/>
<display value="Comparator Description"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<entry>🔗
<reference value="ActivityDefinition/375181"/>
<type value="ActivityDefinition"/>
<display value="Candesartan 8 mg once daily"/>
</entry>
</section>
<section>
<title value="Group Assignment (EvidenceVariable)"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="GroupAssignment"/>
<display value="GroupAssignment"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/375183"/>
<type value="EvidenceVariable"/>
<display value="GroupAssignment: Quadpill vs. Candesartan"/>
</entry>
</section>
</section>
<section>
<title value="Research Study"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="research-study"/>
<display value="Research Study"/>
</coding>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><span style="color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Trial registration number: </span><a style="box-sizing: inherit; background-color: rgb(255, 255, 255); color: rgb(0, 113, 188); text-decoration: none; font-family: BlinkMacSystemFont, -apple-system, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal;" href="http://clinicaltrials.gov/show/NCT03640312" title="See in ClinicalTrials.gov">NCT03640312</a><span style="color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">.</span></p></div>
</text>
<entry>🔗
<reference value="ResearchStudy/367879"/>
<type value="ResearchStudy"/>
<display
value="Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension"/>
</entry>
</section>
<section>
<title value="Methods Section"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="methods"/>
<display value="Methods"/>
</coding>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><span style="color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">QUARTET USA was a randomized (1:1), double-blinded trial conducted in federally qualified health centers among adults with hypertension. Participants received either a quadpill of candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg or candesartan 8 mg for 12 weeks. If BP was >130/>80 mm Hg at 6 weeks in either arm, then participants received open label add-on amlodipine 5 mg. </span></p><p><span style="color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">The primary outcome was mean change in systolic blood pressure (SBP) at 12 weeks, controlling for baseline BP. Secondary outcomes included mean change in diastolic blood pressure (DBP), and safety included serious adverse events, relevant adverse drug effects, and electrolyte abnormalities. </span></p></div>
</text>
</section>
<section>
<title value="Baseline Characteristics"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="baseline-characteristics"/>
<display value="Baseline Characteristics"/>
</coding>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><span style="color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Among 62 participants randomized between August 2019-May 2022 (n = 32 intervention, n = 30 control), mean (SD) age was 52 (11.5) years, 45% were female, 73% identified as Hispanic, and 18% identified as Black. Baseline mean (SD) SBP was 138.1 (11.2) mmHg, and baseline mean (SD) DBP was 84.3 (10.5) mmHg. </span></p></div>
</text>
<entry>
<reference value="Composition/370510"/>
<type value="Composition"/>
<display value="Baseline Characteristics Report for QUARTET Trial"/>
</entry>
</section>
<section>
<title value="Participant Flow"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="participant-flow"/>
<display value="Participant Flow"/>
</coding>
<text value="Participant Flow"/>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<entry>🔗
<reference value="Composition/370512"/>
<type value="Composition"/>
<display value="Participant Flow Report for QUARTET USA Trial"/>
</entry>
</section>
<section>
<title value="Outcome Variables"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measures"/>
<display value="Outcome Measures"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<entry>🔗
<reference value="List/375184"/>
<type value="List"/>
<display value="Outcome Measure List for QUARTET USA Trial"/>
</entry>
</section>
<section>
<title value="Outcome Findings"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-findings"/>
<display value="Outcome Findings"/>
</coding>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><span style="color: rgb(33, 33, 33); font-family: BlinkMacSystemFont, -apple-system, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">In a modified intention-to-treat analysis, there was no significant difference in SBP (-4.8 mm Hg [95% CI: -10.8, 1.3, p = 0.123] and a -4.9 mmHg (95% CI: -8.6, -1.3, p = 0.009) greater mean DBP change in the intervention arm compared with the control arm at 12 weeks. Adverse events did not differ significantly between arms. The quadpill had a similar SBP and greater DBP lowering effect compared with candesartan 8 mg. </span></p></div>
</text>
<entry>🔗
<reference value="Composition/375280"/>
<type value="Composition"/>
<display value="Outcome Measure Report for QUARTET USA Trial"/>
</entry>
</section>
<section>
<title value="Summary of Findings"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings"/>
<display value="Summary of Findings"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Discussion Section"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="discussion"/>
<display value="Discussion"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="References Section"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="references"/>
<display value="References"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<entry>🔗
<reference value="Citation/367878"/>
<type value="Citation"/>
<display
value="Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial. (367878)"/>
</entry>
</section>
<section>
<title value="Competing Interests Section"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="competing-interests"/>
<display value="Competing Interests"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Acknowledgements Section"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="acknowledgements"/>
<display value="Acknowledgements"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Appendices Section"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="appendices"/>
<display value="Appendices"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
</Composition>
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot2 based on FHIR 6.0.0-ballot3. Generated 2025-09-04
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change